(Q34746522)

4 August 2017

1 reference

title

Drugs and their molecular targets: an updated overview (English)

1 reference

4 August 2017

Yves Landry

1

1 reference

4 August 2017

Jean-Pierre Gies

series ordinal

2

1 reference

4 August 2017

publication date

1 February 2008

1 reference

Fundamental and Clinical Pharmacology

4 August 2017

published in

1 reference

4 August 2017

volume

22

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

1-18

1 reference

Progress and problems in the exploration of therapeutic targets

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Drugs, their targets and the nature and number of drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

How many drug targets are there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Proteasome as an emerging therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Development of integrase inhibitors for treatment of AIDS: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Targeting the methyl erythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Multiple molecular mechanisms for multidrug resistance transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Ion channel pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Towards the discovery of novel T-type calcium channel blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

The M3 receptor-mediated K(+) current (IKM3), a G(q) protein-coupled K(+) channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Calcium-activated potassium channels and the regulation of vascular tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Cyclic nucleotide-gated ion channels in sensory transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Transient receptor potential cation channels in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Transient receptor potential channels as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

21 January 2018

TRP proteins and cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Physiology and pathophysiology of purinergic neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

NMDA receptor subunits: function and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

AMPA receptor potentiators: application for depression and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Central nicotinic receptors: structure, function, ligands, and therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Glycine receptors: recent insights into their structural organization and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

JAK/STAT signal transduction: regulators and implication in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

SLAM and CD31: signaling molecules involved in cytokine secretion during the development of innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Small molecular anti-cytokine agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Targeting the ERK signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Heptahelical and other G-protein-coupled receptors (GPCRs) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Orphan neuropeptides. Novel neuropeptides modulating sleep or feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Integrin-associated protein (CD47) and its ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Targeting CD47: NO limit on therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Heterotrimeric G proteins control diverse pathways of transmembrane signaling, a base for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Phosphoinositide 3-kinases as targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Resveratrol is a class IA phosphoinositide 3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Safety issues and prospects for future generations of PPAR modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

RXR: from partnership to leadership in metabolic regulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Role of FXR in regulating bile acid homeostasis and relevance for human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

The regulation of the inflammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Epigenetic marking and neuronal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

Increasing Survival of Ischemic Tissue by Targeting CD47

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00548.X

10.1111/J.1472-8206.2007.00548.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference